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Acute lymphoblastic leukemia (ALL) represents one of the most common malignant diseases of childhood, accounts for about 15 \~ 25% of acute leukemia in adults \[[@CR1]\]. Adult ALL is generally characterized by diverse biological features, evident clinical heterogeneity, and worse prognosis than pediatric ALL \[[@CR2]\]. With the development of genetics in ALL, several new subtypes of ALL and a series of prognostic-related molecular markers are put forward \[[@CR3]--[@CR5]\].

In the recent years, with the application of next-generation sequencing (NGS) technology, genomics has been extensively developed in both pediatric and adult ALL patients \[[@CR6]\]. Samples and clinical information were collected from 121 adult ALL patients (Additional file [1](#MOESM1){ref-type="media"}:Table S1) with informed consent (ethical approval *serial number is* KT2015001-EC-1). These patients were from the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences. Target regions of 112 genes (Additional file [2](#MOESM2){ref-type="media"}: Table S2) were selected on the basis of known or suspected involvement in the pathogenesis of malignant hematologic disorder and were enriched and analyzed using a custom targeted NGS gene panel (Additional file [3](#MOESM3){ref-type="media"}). Then, the relationships between the mutations with higher incidence and the prognosis of ALL patients were analyzed (Additional file [4](#MOESM4){ref-type="media"}).

Of the 121 patients, a total of 110 patients (90.9%) harbored at least one gene mutation with a median of 2 (0--7) mutations per sample. Thirty-nine patients (32.2%) had more than 3 gene mutations (Additional file [5](#MOESM5){ref-type="media"}: Figure S1). Sixty genes were considered as possible pathogenic mutations when compared against multiple databases (Fig. [1a](#Fig1){ref-type="fig"}. The top 38 mutated genes were listed). The five most frequently mutated genes were *FAT1*, *NOTCH1*, *SF1*, *CRLF2*, and *NRAS* (mutated in \>8% of the cases).Fig. 1Frequency of gene mutations and related signal pathways in ALL subtypes. **a** Frequency of the top 38 gene mutations in different ALL subtypes, which are shown in indicated colors. **b** Frequency of gene mutations involved in different functional pathways

In 28 T-ALL cases, the most common mutated gene was *NOTCH1*, with a mutation rate of 39.3% (*n* = 11), then *JAK3*, *FBXW7*, *FAT1*, *NRAS*, *CREBBP*, *DNM2* (mutated in \>10% of the cases) (Additional file [6](#MOESM6){ref-type="media"}: Figure S2A). In B-ALL, FAT1 was the most accepted mutated gene (10.75%), then *SF1*, *CRLF2*, *TET2*, *PTPN11*, *NRAS*, *CREBBP*, *JAK2*, *DIS3*, *MPL*, and *KML2D* (mutated in \>5% of the cases) (Additional file [6](#MOESM6){ref-type="media"}: Figure S2B). In Ph^+^ B-ALL, *FAT1*, *CRLF2*, *SF1*, *EP300*, and *CREBBP* genes mutated at higher incidences (Additional file [6](#MOESM6){ref-type="media"}: Figure S2C). However, *PTPN11*, *SF1*, *TET2*, *NRAS*, *JAK2*, *DIS3*, and *FAT1* gene mutations occurred popularly in Ph^−^B-ALL (Additional file [6](#MOESM6){ref-type="media"}: Figure S2D).

The main signaling pathways involved in this targeted NGS gene panel were transcription factor/regulator, Ras/protein phosphatase/MARK signaling pathway, *JAK-STAT* pathway, splicing and mRNA processing regulation, epigenetic modulators, and so on \[[@CR7]--[@CR9]\]. Frequencies of different signaling pathways involved are listed in Fig. [1b](#Fig1){ref-type="fig"}. Genes involved in these signaling pathways are listed in Additional file [7](#MOESM7){ref-type="media"}:Table S3.

In full cohort, the median overall survival (OS) was 34.88 (1.25--74.55) months, median relapse-free survival (RFS) was 30.85 (0--73.55) months and 3-year OS and RFS rates were 49%. In the full cohort, patients with *PTPN11* mutation had a better prognosis compared with patients without *PTPN11* mutation (*p* = 0.040, *p* = 0.047), and the patients with *JAK2* mutation (7/117) had a worse prognosis compared with patients without *JAK2* mutation (*p* = 0.031, *p* = 0.018) (Additional file [8](#MOESM8){ref-type="media"}: Figure S3). B-ALL patients with *PTPN11* mutation (7/93) had a better OS and RFS compared with those without *PTPN11* mutation (*p* = 0.041, *p* = 0.047) (Additional file [9](#MOESM9){ref-type="media"}: Figure S4).

In T-ALL, patients with *NOTCH1* and/or *FBXW7* mutations had a better OS and RFS than patients without these mutations (*p* = 0.035, *p* = 0.048) (Additional file [10](#MOESM10){ref-type="media"}: Figure S5).

Multivariate analysis of OS and RFS showed that the prognostic factors included *JAK2* mutations (OS; *p*= 0.045, RFS; *p* = 0.021) in the total adult ALL patients cohort. *JAK1* mutations (OS; *p* = 0.004, RFS; *p* = 0.005) and *JAK2* mutations (OS; *p* = 0.049, RFS; *p* = 0.044) for Ph^−^B-ALL. The data was summarized in Table [1](#Tab1){ref-type="table"}.Table 1Univariate and multivariate analysis for OS and RFSOSRFSHR^2^*P* valueHR^2^*P* valueUnivarite analysis (mut/all) PTPN11 mut; positive vs negative in full cohort (8/117)0.0430.0400.0440.047  In B-ALL (7/92)0.0420.0410.0420.047  In Ph^−^B-ALL (7/54)0.0350.0300.0370.047 JAK2 Mut; positive vs negative in full cohort (7/117)3.020.0313.3090.018  In B-ALL (5/92)3.0330.0613.1450.051  In Ph^−^B-ALL (5/54)3.7280.0353.7800.031 JAK1 mut; positive vs negative in Ph^−^B-ALL (4/54)6.8080.0016.5620.001 NOTCH1 and/or FBXW7 mut; positive vs negative  In T-ALL (12/25)0.2040.0350.2230.048Multivariate analysis PTPN11 mut; positive vs negative in full cohort0.0430.0520.0440.056  In B-ALL0.0420.0630.0420.056  In Ph^−^B-ALL0.0350.1780.0370.212 JAK2 mut; positive vs negative in full cohort3.020.0453.3090.021  In Ph^−^B-ALL3.7280.0493.7800.044 JAK1 mut; positive vs negative in Ph^−^B-ALL6.8080.0046.5620.005 NOTCH1 and/or FBXW7 mut; positive vs negative  In T-ALL0.2040.0550.2230.069

In summary, our study suggests that gene mutations exists in adult ALL patients universally, involving a variety of signaling pathways. The frequency and species are varied in different types of ALL. B-ALL patients were accompanied with *PTPN11* mutation for good prognosis, while abnormal *JAK* family often indicates poor prognosis. In T-ALL, mutation of *NOTCH1* and/or *FBXW7* indicates good prognosis.
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